Jupiter Stock Soars After $100 Million ALA-002 Licensing Deal

Jupiter Neurosciences, Inc. (NASDAQ:JUNS) shares are trading higher Wednesday after the company announced it will acquire the U.S. licensing rights to ALA-002 from Pharmala Biotech.